t
Coiled Therapeutics plc announced the results of its Annual General Meeting held on 24 June 2026. All resolutions except resolution 5 were passed by the required majority. Resolution 5, concerning the re-appointment of Pamela Grand Frank as a non-executive director, failed with 3.9189% of votes cast for, resulting in the cessation of her directorship at the conclusion of the AGM.
| Date | 24 Jun 2026 |
| Time | 11:18:46 |
| Category | AGMs and other meetings |
| ID | 5983J |
24 June 2026
Coiled Therapeutics plc
("Coiled Therapeutics" or the "Company")
Result of Annual General Meeting
Coiled Therapeutics (AIM: COIL) (OTCQB: COTFX) announces the results of voting on the resolutions at its Annual General Meeting ("AGM") held today. A poll was held on each resolution and all resolutions except resolution 5 were passed by the required majority. The results of the poll vote can be found below:
|
Resolution |
Votes for |
% Votes Cast |
Votes against |
% Votes Cast |
Total Votes |
Votes withheld |
|
Resolution 1 (Ordinary) |
162,528,440 |
99.9999% |
117 |
0.0001% |
162,528,557 |
20 |
|
Resolution 2 (Ordinary) |
162,511,994 |
99.9960% |
6,563 |
0.0040% |
162,518,557 |
10,020 |
|
Resolution 3 (Ordinary) |
162,508,941 |
99.9955% |
7,257 |
0.0045% |
162,516,198 |
12,379 |
|
Resolution 4 (Ordinary) |
162,524,346 |
99.9975% |
4,061 |
0.0025% |
162,528,407 |
170 |
|
Resolution 5 (Ordinary) |
6,369,320 |
3.9189% |
156,159,087 |
96.0811% |
162,528,407 |
170 |
|
Resolution 6 (Ordinary) |
162,524,346 |
99.9975% |
4,061 |
0.0025% |
162,528,407 |
170 |
|
Resolution 7 (Ordinary) |
162,523,652 |
99.9971% |
4,755 |
0.0029% |
162,528,407 |
170 |
|
Resolution 8 (Ordinary) |
162,524,346 |
99.9975% |
4,061 |
0.0025% |
162,528,407 |
170 |
|
Resolution 9 (Ordinary) |
162,523,646 |
99.9971% |
4,755 |
0.0029% |
162,528,401 |
170 |
|
Resolution 10 (Ordinary) |
162,524,496 |
99.9975% |
4,061 |
0.0025% |
162,528,557 |
20 |
|
Resolution 11 (Ordinary) |
162,514,496 |
99.9975% |
4,061 |
0.0025% |
162,518,557 |
10,020 |
|
Resolution 12 (Ordinary) |
162,514,745 |
99.9917% |
13,455 |
0.0083% |
162,528,200 |
377 |
|
Resolution 13 (Special) |
162,504,683 |
99.9856% |
23,483 |
0.0144% |
162,528,166 |
405 |
Resolution 5 related to the re‑appointment of Pamela Grand Frank as a non‑executive director; as the resolution was not passed, Ms Frank has not been re‑appointed, and Ms Frank's directorship therefore ceased at the conclusion of the AGM.
As at 24 June 2026, there were 426,791,322 ordinary shares in issue. Shareholders are entitled to one vote per share. Votes withheld are not votes in law and have not been included in the calculation of the proportion of votes for or against a resolution.
-Ends-
Enquiries:
|
Coiled Therapeutics plc Sotirios Stergiopoulos (Chairman) Sridhar Vempati (CEO)
|
Via Burson Buchanan |
|
SP Angel Corporate Finance LLP (Nominated Adviser & Joint Broker) David Hignell / Adam Cowl / Devik Mehta (Corporate Finance) Vadim Alexandre / Rob Rees (Corporate Broking)
|
+44 (0)20 3470 0470
|
|
Shard Capital Partners LLP (Joint Broker) Damon Heath
CPS Capital Group Pty Ltd (Joint Broker) Jason Peterson / David Valentino
|
+44 (0)20 4530 6926
+61 (0)8 9223 2222
|
|
Burson Buchanan (Public Relations) Henry Harrison Topham / Jamie Hooper / Toto Berger |
+44 (0)20 7466 5000
|
|
|
|
|
Harbor Access (US Investor Relations) Matt Kelly / Jonathan Paterson |
+1 475 477 9404 |
About Coiled Therapeutics plc
Coiled Therapeutics (AIM: COIL) (OTCQB: COTXF) is an AIM-listed, clinical-stage biotechnology company focused on developing innovative precision oncology therapies. Its lead programme, AO-252, is a novel TACC3 inhibitor currently in Phase I clinical trials in the USA (trials ID: NCT06136884). Coiled Therapeutics is actively enrolling patients to test for safety and efficacy in patients whose cancer has progressed on other treatments. The Company is also assessing its STAT-6 siRNA programme for immunology indications. Coiled Therapeutics is supported by a leadership team with a proven track record in drug development and strategic backing from A2A Pharmaceuticals.
About AO-252
AO-252 is a first-in-class, orally administered, brain-penetrant small molecule inhibitor of Transforming Acidic Coiled-Coil containing protein 3 (TACC3). TACC3 is a validated oncology target that is frequently overexpressed in many aggressive, hard-to-treat solid tumours but is dispensable in normal adult cells, providing a wide therapeutic window.
By selectively disrupting cancer-critical protein-protein interactions at the TACC3 C-terminal domain, AO-252 induces mitotic and replication stress, impairs DNA damage repair, and triggers cancer cell death. Notably, AO-252 has demonstrated the ability to cross the blood-brain barrier, addressing a significant unmet medical need for the treatment of brain metastases.
The asset is currently being evaluated in an ongoing Phase I open-label dose-escalation study. The Company plans to initiate dose-expansion cohorts in lead indications, including prostate and ovarian cancer, during 2026.
For more information, please visit: www.coiledplc.com